Amelioration of high-fat diet (HFD) + CCl4 induced NASH/NAFLD in CF-1 mice by activation of SIRT-1 using cinnamoyl sulfonamide hydroxamate derivatives: in-silico molecular modelling and in-vivo prediction
Abstract Non-alcoholic fatty liver disease (NAFLD) is one of the major hepatic metabolic disorders that occurs because of the accumulation of lipids in hepatocytes in the form of free fatty acids (FFA) and triglycerides (TG) which become non-alcoholic steatohepatitis (NASH). NOTCH-1 receptors act as novel targets for the development of NAFLD/NASH, where overexpression of NOTCH-1 receptor alters the lipid metabolism in hepatocytes leading to NAFLD. SIRT-1 deacetylates the NOTCH-1 receptor and inhibits NAFLD. Hence, computer-aided drug design (CADD) was used to check the SIRT-1 activation ability of cinnamic sulfonyl hydroxamate derivatives (NMJ 1–8), resveratrol, and vorinostat. SIRT-1 (PDB ID: 5BTR) was docked with eight hydroxamate derivatives and vorinostat using Schrödinger software. Based on binding energy obtained (– 26.31 to – 47.34 kcal/mol), vorinostat, NMJ-2, NMJ-3, NMJ-5 were selected for induced-fit docking (IFD) and results were within – 750.70 to – 753.22 kcal/mol. Qikprop tool was used to analyse the pre pharmacokinetic parameters (ADME analysis) of all hydroxamate compounds. As observed in the molecular dynamic (MD) study, NMJ-2, NMJ-3 were showing acceptable results for activation of SIRT-1. Based on these predictions, in-vivo studies were conducted in CF1 mice, where NMJ-3 showed significant (p < 0.05) changes in lipid profile and anti-oxidant parameters (Catalase, SOD, GSH, nitrite, and LPO) and plasma insulin levels. NMJ-3 treatment also reduced inflammation, fibrosis, and necrosis in liver samples..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
3 Biotech - 12(2022), 7 vom: 15. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sodum, Nalini [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
ADME |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s13205-022-03192-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR047292989 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR047292989 | ||
| 003 | DE-627 | ||
| 005 | 20230519065708.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220616s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13205-022-03192-5 |2 doi | |
| 035 | |a (DE-627)SPR047292989 | ||
| 035 | |a (SPR)s13205-022-03192-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sodum, Nalini |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Amelioration of high-fat diet (HFD) + CCl4 induced NASH/NAFLD in CF-1 mice by activation of SIRT-1 using cinnamoyl sulfonamide hydroxamate derivatives: in-silico molecular modelling and in-vivo prediction |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Abstract Non-alcoholic fatty liver disease (NAFLD) is one of the major hepatic metabolic disorders that occurs because of the accumulation of lipids in hepatocytes in the form of free fatty acids (FFA) and triglycerides (TG) which become non-alcoholic steatohepatitis (NASH). NOTCH-1 receptors act as novel targets for the development of NAFLD/NASH, where overexpression of NOTCH-1 receptor alters the lipid metabolism in hepatocytes leading to NAFLD. SIRT-1 deacetylates the NOTCH-1 receptor and inhibits NAFLD. Hence, computer-aided drug design (CADD) was used to check the SIRT-1 activation ability of cinnamic sulfonyl hydroxamate derivatives (NMJ 1–8), resveratrol, and vorinostat. SIRT-1 (PDB ID: 5BTR) was docked with eight hydroxamate derivatives and vorinostat using Schrödinger software. Based on binding energy obtained (– 26.31 to – 47.34 kcal/mol), vorinostat, NMJ-2, NMJ-3, NMJ-5 were selected for induced-fit docking (IFD) and results were within – 750.70 to – 753.22 kcal/mol. Qikprop tool was used to analyse the pre pharmacokinetic parameters (ADME analysis) of all hydroxamate compounds. As observed in the molecular dynamic (MD) study, NMJ-2, NMJ-3 were showing acceptable results for activation of SIRT-1. Based on these predictions, in-vivo studies were conducted in CF1 mice, where NMJ-3 showed significant (p < 0.05) changes in lipid profile and anti-oxidant parameters (Catalase, SOD, GSH, nitrite, and LPO) and plasma insulin levels. NMJ-3 treatment also reduced inflammation, fibrosis, and necrosis in liver samples. | ||
| 650 | 4 | |a NOTCH-1 receptor |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SIRT-1 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a NAFLD/NASH |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a ADME |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Molecular dynamics |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Anti-oxidants |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Rao, Vanishree |4 aut | |
| 700 | 1 | |a Cheruku, Sri Pragnya |4 aut | |
| 700 | 1 | |a Kumar, Gautam |4 aut | |
| 700 | 1 | |a Sankhe, Runali |4 aut | |
| 700 | 1 | |a Kishore, Anoop |4 aut | |
| 700 | 1 | |a Kumar, Nitesh |4 aut | |
| 700 | 1 | |a Rao, C. Mallikarjuna |0 (orcid)0000-0003-3744-8135 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t 3 Biotech |d Berlin : Springer, 2011 |g 12(2022), 7 vom: 15. Juni |w (DE-627)SPR030851394 |w (DE-600)2600522-0 |x 2190-5738 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:7 |g day:15 |g month:06 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13205-022-03192-5 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 7 |b 15 |c 06 | ||